From: Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer
Characteristic | N (%) | |
---|---|---|
Male | 25(55.6 %) | |
Age (years) Median, [IQR] | 54.5, [41.5,62.4] | |
Body Mass Index (Kg/m2) Median, [IQR] | 27.2, [23.4, 33.4] | |
Malignancy type | ||
Hematologic | 15 (33.3 %) | |
Solid | 24 (53.3 %) | |
Primary CNS | 5 (11.1 %) | |
Concurrent solid and CNS | 1 (2.2 %) | |
Malignancy status | ||
Active | 32 (71.1 %) | |
Remission < 2 years | 8 (17.8 %) | |
Remission > 2 years | 4 (8.9 %) | |
Staging (AJCC) | ||
1 | 8 (17.8 %) | |
2 | 4 (8.9 %) | |
3 | 5 (11.1 %) | |
4 | 17 (37.8 %) | |
Active chemotherapy | 20 (44.4 %) | |
Hormonal cancer therapy | 4 (8.9 %) | |
Tyrosine kinase inhibitor | 1 (2.2 %) | |
Use of ESA | 1 (2.2 %) | |
Recent major surgery | 27 (60.0 %) | |
Multifocal CVT | 26 (57.8 %) | |
Occlusive CVT | 14 (31.1 %) | |
Concurrent brain venous infarction | 12 (26.7 %) | |
Concurrent brain parenchyma hemorrhage | 16 (35.6 %) |